Mintzes, Barbara - University of Sydney

研究领域

Dr Mintzes’ research focuses primarily on quality use of medicines, through studies that build the scientific evidence to support appropriate prescribing and use of medicines, and through evaluations of the effectiveness of policies aiming to support quality medicine use. In the field of pharmaceutical policy, she has conducted research on pharmaceutical promotion, comparing the content of promotional information provided to consumers and physicians with the scientific evidence, and comparing national approaches to regulation and regulatory standards with promotional content. Her second related interest is the study of ‘disease-mongering’, i.e. commercial influences on diagnostic criteria and on the thresholds for treatment of specific conditions. Current research projects include: a comparative evaluation of regulatory safety advisories on medicines in four countries over a 10-year period; an evaluation of antidepressant use in pregnancy in British Columbia; a systematic review of the beneficial and harmful effects of postpartum domperidone use to stimulate lactation; a systematic review of disease-awareness advertising; and an evaluation of the strength of evidence supporting recommendations for ‘off-label’ use of pharmaceuticals in a prescribing guide. With the Charles Perkins Centre, Dr Mintzes’ research will evaluate how diagnostic thresholds and treatment outcomes are assessed in obesity, diabetes and cardiovascular disease, and particularly the influence of commercial interests. A second focus is the study of medications with cardiovascular and metabolic adverse events.

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Morgan, S., Gagnon, M., Mintzes, B., Lexchin, J. (2016). A better prescription: Advice for a national strategy on pharmaceutical policy in Canada. Healthcare Policy, 12(1), 18-36. Vitry, A., Mintzes, B., Lipworth, W. (2016). Access to new cancer medicines in Australia: dispelling the myths and informing a public debate. Journal of Pharmaceutical Policy and Practice, 9(3), 1-6. [More Information] Hanley, G., Mintzes, B. (2016). In Reply. Obstetrics & Gynecology, 128(2), 406-406. [More Information] Hanley, G., Smolina, K., Mintzes, B., Oberlander, T., Morgan, S. (2016). Postpartum Hemorrhage and Use of Serotonin Reuptake Inhibitor Antidepressants in Pregnancy. Clinical Obstetrics and Gynecology, 127(3), 553-561. [More Information] Cosgrove, L., VAnnoy, S., Mintzes, B., Shaughnessy, A. (2016). Under the Influence: The Interplay among Industry, Publishing, and Drug Regulation. Accountability in Research: policies and quality assurance, 23(5), 257-279. [More Information] Jarvinen, T., Michaelsson, K., Jokihaara, J., Collins, G., Perry, T., Mintzes, B., Musini, V., Erviti, J., Gorricho, J., Wright, J., et al (2015). Authors' reply to lee and colleagues. BMJ, 351, 1-2. [More Information] Mintzes, B., Lexchin, J., Quintano, A. (2015). Clinical trial transparency: Many gains but access to evidence for new medicines remains imperfect. British Medical Bulletin, 116(1), 43-53. [More Information] Jarvinen, T., Michaelsson, K., Jokihaara, J., Collins, G., Perry, T., Mintzes, B., Musini, V., Erviti, J., Gorricho, J., Wright, J., et al (2015). Overdiagnosis of bone fragility in the quest to prevent hip fracture. BMJ, 350, 1-7. [More Information] Smolina, K., Hanley, G., Mintzes, B., Oberlander, T., Morgan, S. (2015). Trends and Determinants of Prescription Drug Use during Pregnancy and Postpartum in British Columbia, 2002-2011: A Population-Based Cohort Study. PloS One, 10(5), 1-16. [More Information] Mintzes, B. (2015). When drugs don't make it to market. BMJ, 350, 1-2. Nguyen, C., MacEntee, M., Mintzes, B., Perry, T. (2014). Information for physicians and pharmacists about drugs that might cause dry mouth: A study of monographs and published literature. Drugs and Aging, 31(1), 55-65. [More Information] Herder, M., Gibson, E., Graham, J., Lexchin, J., Mintzes, B. (2014). Regulating prescription drugs for patient safety: Does Bill C-17 go far enough? CMAJ, 186(8), E287-E292. [More Information] Fortin, P., Mintzes, B., Innes, M. (2013). A Systematic Review of Intravitreal Bevacizumab for the Treatment of Diabetic Macular Edema. Canadian Agency for Drugs and Technologies in Health, 3(1), 12-19. Mintzes, B., Smith, M. (2013). Evidence-based medicine: Strengths and limitations. Australian Prescriber, 36(S2), 17-21. Mintzes, B. (2013). Medication safety: opening up the black box. BMJ Quality and Safety, 22(9), 702-704. [More Information] Mintzes, B., Lexchin, J., Wilkes, M., Beaulieu, M., Reynolds, E., Sutherland, J., Durrieu, G. (2013). Pharmaceutical sales representatives and patient safety. Journal of General Internal Medicine, 28(11), 1395-1395. [More Information] Mintzes, B., Lexchin, J., Sutherland, J., Beaulieu, M., Wilkes, M., Durrieu, G., Reynolds, E. (2013). Pharmaceutical sales representatives and patient safety: A comparative prospective study of information quality in Canada, France and the United States. Journal of General Internal Medicine, 28(10), 1368-1375. [More Information] Shnier, A., Lexchin, J., Mintzes, B., Jutel, A., Holloway, K. (2013). Too Few, Too Weak: Conflict of Interest Policies at Canadian Medical Schools. PloS One, 8(7), 1-9. [More Information] Mintzes, B. (2012). Advertising of prescription-only medicines to the public: Does evidence of benefit counterbalance harm? Annual Review of Public Health, 33(21 April), 259-277. [More Information] Tejani, A., Siu, J., Wright, J., Bassett, K., Musini, V., Mintzes, B., Perry, T. (2012). Another hypertension visit. Canadian family physician (medcin de famille canadien), 58(8), 829-830.